James Saller, MD; Sameer Al Diffalha; Kevin Neill; Cecilia Oliveri; Hank Levine; David Boulware and Domenico Coppola, M.D.
This study demonstrates the utility of CDX2 IHC for determining patients with a higher likelihood of harboring intestinal metaplasia undetected by the ABPAS stain at their first biopsy. Our findings show that patients with biopsies that are ABPAS negative and CDX2 positive at their first presentation may later present with frank goblet cell intestinal metaplasia.
